# SUPERIOR GROUP OF COMPANIES, INC. (SGC)

Informational only - not investment advice.

CIK: 0000095574
SIC: 2300 Apparel & Other Finishd Prods of  Fabrics & Similar Matl
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 23](/major-group/23/) > [SIC 2300 Apparel & Other Finishd Prods of  Fabrics & Similar Matl](/industry/2300/)
Latest 10-K filed: 2026-03-03
SEC page: https://www.sec.gov/edgar/browse/?CIK=95574
Filing source: https://www.sec.gov/Archives/edgar/data/95574/000143774926006653/sgc20251231_10k.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-03 · accession 0001437749-26-006653 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000095574.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 566,184,000 USD | 2025 | verified |
| Net income | 7,000,000 USD | 2025 | verified |
| Assets | 421,844,000 USD | 2025 | verified |
| Free cash flow | 15,762,000 USD | 2025 | computed |
| Net margin | 1.24% | 2025 | computed |
| Revenue YoY | +0.09% | 2025 | computed |
| ROE | 3.63% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.


## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 566184000 | USD | 2025 | 2026-03-03 |
| Net income | 7000000 | USD | 2025 | 2026-03-03 |
| Assets | 421844000 | USD | 2025 | 2026-03-03 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000095574.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2013 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 252,596,000 | 266,814,000 | 346,350,000 | 376,701,000 | 526,697,000 | 536,986,000 | 578,831,000 | 543,302,000 | 565,676,000 | 566,184,000 |
| Net income |  | 14,638,000 | 15,022,000 | 16,975,000 | 12,066,000 | 41,026,000 | 29,440,000 | -31,970,000 | 8,772,000 | 12,004,000 | 7,000,000 |
| Gross profit |  | 86,982,000 | 96,352,000 | 121,697,000 | 128,929,000 | 188,765,000 | 186,014,000 | 193,359,000 | 203,547,000 | 220,578,000 | 212,864,000 |
| Diluted EPS |  | 0.98 | 0.99 | 1.10 | 0.79 | 2.65 | 1.83 | -2.03 | 0.54 | 0.73 | 0.46 |
| Operating cash flow |  | 11,989,000 | 22,727,000 | 19,864,000 | 20,007,000 | 41,359,000 | 17,080,000 | -2,604,000 | 78,929,000 | 33,428,000 | 19,709,000 |
| Capital expenditures |  | 7,385,000 | 4,248,000 | 4,869,000 | 9,672,000 | 11,857,000 | 17,696,000 | 11,018,000 | 4,963,000 | 4,435,000 | 3,947,000 |
| Dividends paid |  | 4,707,000 | 5,269,000 | 5,836,000 | 6,046,000 | 6,111,000 | 7,237,000 | 8,653,000 | 9,188,000 | 9,284,000 | 8,905,000 |
| Share buybacks | 162,000 | 714,000 |  | 2,906,000 | 1,685,000 | 500,000 | 0.00 | 0.00 | 0.00 | 7,417,000 | 10,136,000 |
| Assets |  | 196,848,000 | 218,938,000 | 335,086,000 | 358,933,000 | 393,924,000 | 470,245,000 | 456,941,000 | 422,450,000 | 415,134,000 | 421,844,000 |
| Liabilities |  |  |  |  |  |  |  | 264,342,000 | 224,812,000 | 216,278,000 | 229,026,000 |
| Stockholders' equity |  | 110,550,000 | 124,968,000 | 150,921,000 | 157,554,000 | 191,630,000 | 226,990,000 | 192,599,000 | 197,638,000 | 198,856,000 | 192,818,000 |
| Cash and cash equivalents |  | 3,649,000 | 8,130,000 | 5,362,000 | 9,038,000 | 5,172,000 | 8,935,000 | 17,722,000 | 19,896,000 | 18,766,000 | 23,691,000 |
| Free cash flow |  | 4,604,000 | 18,479,000 | 14,995,000 | 10,335,000 | 29,502,000 | -616,000 | -13,622,000 | 73,966,000 | 28,993,000 | 15,762,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2013 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 5.80% | 5.63% | 4.90% | 3.20% | 7.79% | 5.48% | -5.52% | 1.61% | 2.12% | 1.24% |
| Return on equity |  | 13.24% | 12.02% | 11.25% | 7.66% | 21.41% | 12.97% | -16.60% | 4.44% | 6.04% | 3.63% |
| Return on assets |  | 7.44% | 6.86% | 5.07% | 3.36% | 10.41% | 6.26% | -7.00% | 2.08% | 2.89% | 1.66% |
| Liabilities / equity |  |  |  |  |  |  |  | 1.37 | 1.14 | 1.09 | 1.19 |
| Current ratio |  | 3.92 | 3.31 | 4.25 | 3.05 | 2.37 | 2.69 | 3.73 | 2.78 | 2.68 | 2.66 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-04. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000095574.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.80 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.06 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.08 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 136,126,000 | 3,114,000 | 0.19 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 147,241,000 | 3,557,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 138,842,000 | 3,912,000 | 0.24 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 131,736,000 | 600,000 | 0.04 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 149,690,000 | 5,403,000 | 0.33 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 145,408,000 | 2,089,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 137,097,000 | -758,000 | -0.05 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 144,045,000 | 1,551,000 | 0.10 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 138,467,000 | 2,744,000 | 0.18 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 146,575,000 | 3,463,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 140,878,000 | 834,000 | 0.06 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 147,836,000 | 1,221,000 | 0.08 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from SGC's latest 10-K: [/company/SGC/business/](/company/SGC/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from SGC's latest 10-K: [/company/SGC/risk-factors/](/company/SGC/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/95574/000143774926025511/sgc20260630_10q.htm

Extracted from a substantive MD&A body after the formal Item 2 span was a TOC or reference stub.
Confidence: high
Filing date: 2026-08-04
Report date: 2026-06-30

Results of Operations

Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025 (in thousands)

[[GREPCENT_TABLE]]
[["","For the Three Months Ended June 30,"],["","2026","","2025","","$ Change","","% Change"],["Net sales:"],["Branded Products","$","98,390","","$","92,647","","$","5,743","","","6.2","%"],["Healthcare Apparel","","27,231","","","28,253","","","(1,022",")","","(3.6","%)"],["Contact Centers","","23,094","","","23,977","","","(883",")","","(3.7","%)"],["Intersegment eliminations","","(879",")","","(832",")","","(47",")","","5.6","%"],["Consolidated net sales","","147,836","","","144,045","","","3,791","","","2.6","%"],["Gross margin:"],["Branded Products","","35,872","","","33,016","","","2,856","","","8.7","%"],["Healthcare Apparel","","8,967","","","10,016","","","(1,049",")","","(10.5","%)"],["Contact Centers","","11,750","","","12,613","","","(863",")","","(6.8","%)"],["Net intersegment eliminations","","(470",")","","(319",")","","(151",")","","47.3","%"],["Consolidated gross margin","","56,119","","","55,326","","","793","","","1.4","%"],["Selling and administrative expenses:"],["Branded Products","","26,001","","","25,432","","","569","","","2.2","%"],["Healthcare Apparel","","9,946","","","10,078","","","(132",")","","(1.3","%)"],["Contact Centers","","10,354","","","11,612","","","(1,258",")","","(10.8","%)"],["Intersegment Eliminations","","(470",")","","(319",")","","(151",")","","47.3","%"],["Corporate selling and administrative expenses","","5,496","","","5,437","","","59","","","1.1","%"],["Consolidated selling and administrative expenses","","51,327","","","52,240","","","(913",")","","(1.7","%)"],["Interest expense, net","","981","","","1,250","","","(269",")","","(21.5","%)"],["Tradename impairment charge","","2,600","","","-","","","2,600","","","100.0","%"],["Income before income tax expense","","1,211","","","1,836","","","(625",")","","(34.0","%)"],["Income tax (benefit) expense","","(10",")","","285","","","(295",")","","(103.5","%)"],["Net income","$","1,221","","$","1,551","","$","(330",")","","(21.3","%)"],["Adjusted EBITDA(1)","$","7,676","","$","6,064","","$","1,612","","","26.6","%"]]
[[/GREPCENT_TABLE]]

(1) Please refer to "Non-GAAP Financial Measure" below for a reconciliation of Adjusted EBITDA to net income.

24

Table of Contents

Net Income

The Company generated net income of $1.2 million and $1.6 million during the three months ended June 30, 2026 and 2025, respectively. The decrease in net income for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 was due to a significant decline in our Healthcare Apparel segment results, primarily driven by a trade name impairment charge and write-down of inventory, partially offset by net tariff refunds. This decline was partially offset by growth in our Branded Products and Contact Centers segments.

Adjusted EBITDA

Adjusted EBITDA was $7.7 million and $6.1 million during the three months ended June 30, 2026 and 2025, respectively. The Adjusted EBITDA increase was primarily due to growth in our Branded Products and Contact Centers segments, partially offset by a decline in our Healthcare Apparel segment. For a reconciliation of Adjusted EBITDA to net income, its most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), please read “Non-GAAP Financial Measure” below.

Net Sales

Net sales for the Company increased 2.6%, or $3.8 million, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The increase was attributable to increases in net sales in our Branded Products segment, partially offset by declines in our Healthcare Apparel and Contact Centers segments.

Branded Products net sales increased 6.2%, or $5.7 million, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The increase was primarily due to volume increases of $7.5 million within existing customer accounts, partially offset by tariff refunds.

Healthcare Apparel net sales decreased 3.6%, or $1.0 million, for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 primarily due to tariff refunds.

Contact Centers net sales decreased 3.7% or $0.9 million, before intersegment eliminations for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The 3.7% decrease versus the prior period reflects client attrition that exceeded growth from new customer acquisitions. 

25

Table of Contents

Gross Margin

Gross margin rate for the Company was 38.0% for the three months ended June 30, 2026 and 38.4% for the three months ended June 30, 2025. The rate decrease was primarily due to lower gross margin rates in our Healthcare Apparel and Contact Centers segments.

Gross margin rate for our Branded Products segment was 36.5% for the three months ended June 30, 2026 and 35.6% for the three months ended June 30, 2025. The rate increase was primarily driven by a favorable shift in the mix of pricing and customers.

Gross margin rate for our Healthcare Apparel segment was 32.9% for the three months ended June 30, 2026 and 35.5% for the three months ended June 30, 2025. The rate decrease was primarily driven by the impact of a $2.6 million additional write-down of inventory, partially offset by $1.8 million of net tariff refunds.

Gross margin rate for our Contact Centers segment was 50.9% for the three months ended June 30, 2026 and 52.6% for the three months ended June 30, 2025. The decrease in the gross margin rate was primarily attributable to higher employee-related costs as compared to the prior year period.

Selling and Administrative Expenses

Selling and administrative expenses decreased $0.9 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. As a percentage of net sales, total selling and administrative expenses was 34.7% for the three months ended June 30, 2026 and 36.3% for the three months ended June 30, 2025. The rate decrease was driven by expense leverage in our Branded Products segment and lower expenses in our Contact Centers segments.

Branded Products selling and administrative expenses increased $0.6 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. As a percentage of net sales, selling and administrative expenses was 26.4% for the three months ended June 30, 2026, down slightly from 27.5% for the three months ended June 30, 2025 driven by expense leverage from the second quarter sales increase.

Healthcare Apparel selling and administrative expenses decreased $0.1 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. Selling and administrative expenses as a percentage of net sales increased to 36.5% for the three months ended June 30, 2026 from 35.7% for the three months ended June 30, 2025. 

Contact Centers selling and administrative expenses decreased $1.3 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025 due to a reduction in credit loss expense as compared to the prior year period. As a result, selling and administrative expenses as a percentage of net sales decreased to 44.8% for the three months ended June 30, 2026 from 48.4% for the three months ended June 30, 2025. 

Corporate selling and administrative expenses were about flat to last year.

Interest Expense, Net

Interest expense, net decreased to $1.0 million for the three months ended June 30, 2026 from $1.3 million for the three months ended June 30, 2025. This decrease was due to a lower weighted average interest rate on borrowings, from 5.6% for the three months ended June 30, 2025 to 4.8% for the three months ended June 30, 2026.

Intangible Assets Impairment Charge

As a result of  an interim impairment assessment, an impairment charge totaling $2.6 million was recognized in the second quarter of 2026 to reduce the carrying value of Healthcare Apparel trade names to their estimated fair value.

26

Table of Contents

Income Taxes

An income tax benefit of ($0.01) million was recognized for the three months ended June 30, 2026 compared to an income tax expense of $0.3 million for the three months ended June 30, 2025. The effective tax rate was (0.8%) benefit and 15.5% expense for the three months ended June 30, 2026 and 2025, respectively. Income tax expense and the effective tax rate for the three months ended June 30, 2026 was primarily impacted by the discrete tax benefit relating to the $2.6 million trade name impairment charge recorded during the second fiscal quarter of 2026. The rate for both periods was further impacted by the variability in the mix of earnings across the Company’s foreign and domestic operations, subject to various statutory tax rates in those jurisdictions. The effective tax rate may vary from quarter to quarter due to discrete, unusual or non-recurring items, the resolution of income tax audits, changes in tax laws, the tax impact from employee share-based payments, or other items.

27

Table of Contents

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025 (in thousands)

[[GREPCENT_TABLE]]
[["","","For the Six Months Ended June 30,"],["","","2026","","","2025","","","$ Change","","","% Change"],["Net sales:"],["Branded Products","","$","189,259","","","$","179,121","","","$","10,138","","","","5.7","%"],["Healthcare Apparel","","","55,832","","","","55,516","","","","316","","","","0.6","%"],["Contact Centers","","","45,347","","","","48,202","","","","(2,855",")","","","(5.9","%)"],["Intersegment eliminations","","","(1,724",")","","","(1,697",")","","","(27",")","","","1.6","%"],["Consolidated net sales","","","288,714","","","","281,142","","","","7,572","","","","2.7","%"],["Gross margin:"],["Branded Products","","","66,859","","","","60,703","","","","6,156","","","","10.1","%"],["Healthcare Apparel","","","19,148","","","","20,149","","","","(1,001",")","","","(5.0","%)"],["Contact Centers","","","23,364","","","","25,594","","","","(2,230",")","","","(8.7","%)"],["Net intersegment eliminations","","","(918",")","","","(679",")","","","(239",")","","","35.2","%"],["Consolidated gross margin","","","108,453","","","","105,767","","","","2,686","","","","2.5","%"],["Selling and administrative expenses:"],["Branded Products","","","50,747","","","","48,852","","","","1,895","","","","3.9","%"],["Healthcare Apparel","","","20,724","","","","19,604","","","","1,120","","","","5.7","%"],["Contact Centers","","","19,917","","","","22,533","","","","(2,616",")","","","(11.6","%)"],["Intersegment Eliminations","","","(918",")","","","(679",")","","","(239",")","","","35.2","%"],["Corporate selling and administrative expenses","","","11,225","","","","12,032","","","","(807",")","","","(6.7","%)"],["Consolidated selling and administrative expenses","","","101,695","","","","102,342","","","","(647",")","","","(0.6","%)"],["Interest expense, net","","","1,893","","","","2,495","","","","(602",")","","","(24.1","%)"],["Tradename impairment charge","","","2,600","","","","-","","","","2,600","","","","100.0","%"],["Income before income tax expense","","","2,265","","","","930","","","","1,335","","","","143.5","%"],["Income tax expense","","","210","","","","137","","","","73","","","","53.3","%"],["Net income","","$","2,055","","","$","793","","","$","1,262","","","","159.1","%"],["Adjusted EBITDA(1)","","$","12,500","","","$","9,607","","","$","2,893","","","","30.1","%"]]
[[/GREPCENT_TABLE]]

(1) Please refer to "Non-GAAP Financial Measure" below for a reconciliation of Adjusted EBITDA to net income.

28

Table of Contents

Net Income

The Company generated net income of $2.1 million and $0.8 million during the six months ended June 30, 2026 and 2025, respectively. The increase in net income for the six months en

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/95574/000143774926006653/sgc20251231_10k.htm
Complete FY 2025 MD&A: /company/SGC/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-03
Report date: 2025-12-31

Item 7.          Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our Financial Statements, which present our results of operations for the years ended December 31, 2025 and 2024, as well as our financial positions at December 31, 2025 and 2024, contained elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the “Special Note Regarding Forward Looking Statements” and “Risk Factors” sections of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Additionally, we use a non-GAAP financial measure to evaluate our results of operations. For important information regarding the use of such non-GAAP financial measure, including reconciliations to the most comparable GAAP measure, see the section titled “Non-GAAP Financial Measure” below.

Business Outlook

Superior is comprised of three reportable business segments: (1) Branded Products, (2) Healthcare Apparel and (3) Contact Centers. 

Branded Products

In our Branded Products segment, we produce and sell customized merchandising solutions, promotional products and branded uniform programs to our customers. As a strategic branding partner, we offer our customers customized branding solutions and strategies that generate favorable brand impressions, bolster customer retention and enhance employee engagement. Our products are sold to customers in a wide range of industries, including retail, hotel, food service, entertainment, technology, transportation and other industries. Sales volumes in this segment are impacted by a number of factors, including marketing programs of our customers and turnover of our customers’ employees, often times driven by the opening and closing of locations. From a long-term perspective, we believe that synergies within this segment will create opportunities to cross-sell products to new and existing customers.

Healthcare Apparel

In our Healthcare Apparel segment, we manufacture (through third parties or in our own facilities) and sell a wide range of healthcare apparel, such as scrubs, lab coats, protective apparel and patient gowns. We sell our brands of healthcare service apparel to healthcare laundries, dealers, distributors and retailers primarily in the United States. From a long-term perspective, we expect that demand for our portfolio of brands Wink® and Fashion Seal Healthcare®, our trade name CID Resources and our license of Carhartt Medical, will continue to provide opportunities for growth and increased market share.

24

Table of Contents

Contact Centers

In our Contact Centers segment (also known as The Office Gurus), which operates in El Salvador, Belize, Dominican Republic, the United States and Jamaica until its closure on June 15, 2025, we provide outsourced, nearshore and onshore business process outsourcing, contact and call-center support services to North American customers. These services are also provided internally to the Company’s other two operating segments. The Office Gurus has become an award-winning business process outsourcer offering inbound and outbound voice, email, text, chat and social media support. The nearshore call-center market specifically has grown as businesses look to reduce operating costs while maintaining high-quality customer support. Nearshore operators can provide comparable service to their U.S. counterparts at a fraction of the price. With an environment and career path designed to attract and maintain top talent across all sites, we believe The Office Gurus is positioned well to continue growing this business.

Global Economic and Political Conditions

During 2025, the U.S. government imposed higher tariffs and/or new tariffs which impacted certain sources of the Company’s materials and production. Additionally, the U.S.'s trade agreements and/or preferences with certain countries in Africa, through the African Growth and Opportunity Act (AGOA), and with Haiti, through the Haitian Hemispheric Opportunity through Partnership Encouragement Act (HOPE) and the Haiti Economic Lift Program of 2010 (HELP), expired on September 30, 2025. In February 2026, these agreements were retroactively extended until December 2026. The process and timing for receiving a refund of duties paid in the interim period between expiration and when retroactivity was granted has yet to be determined. If not renewed and/or extended after December 2026, the cost of continuing to do business in these countries likely will negatively impact our results of operations and financial position, or result in us moving sourcing and manufacturing from these countries to countries with more favorable cost structures. We will continue to monitor the status of the trade agreements and preferences involving the U.S. government and the countries in which we source and/or manufacture products. See Item 8, “NOTE 7 – Contingencies and Geographic Supply Concentrations,” and "Item 1A — Risk Factors — Recently imposed tariffs may have a material adverse impact on our business." 

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs, effectively invalidating the tariffs imposed via that method.  These IEEPA tariffs stopped being collected at 12:00 a.m. on February 24, 2026.  The Supreme Court’s ruling left open the questions of whether, how, and when payors of the tariffs might receive refunds.  A determination of these, and other questions, could take a significant amount of time to resolve.  Soon after the Supreme Court’s decision, President Trump announced his intention to impose tariffs using different legal bases.  Already, a new 10% tariff has been implemented under Section 122 of the Trade Act of 1974, effective as of February 24, 2026.  The Supreme Court’s ruling and President Trump’s response add new uncertainty to global trade, including the Company’s exposure to tariffs.

It is uncertain how inflation and interest rates will be impacted in 2026 by the imposition of tariffs and other trade-related actions or inactions. World events, such as the Russia-Ukraine War, the joint U.S-Israeli strikes on Iran in February 2026 and other conflicts in the Middle East, continue to negatively affect the global economy. Additionally, civil unrest in countries where we manufacture products, like Haiti, may result in our facilities incurring damage or destruction and could interrupt our manufacturing processes and adversely affect our reputation and our relationships with our customers.

Prolonged or recurring disruptions or instability in the United States and global political and economic environment, and how the world reacts to those disruptions or instability, could have long-term impacts on our business. These business impacts could negatively affect us in a number of ways, including, but not limited to, reduced demand for our core products and services, declines in our revenue and profitability, increased costs related to higher oil and natural gas prices and/or supply imbalances in the oil and natural gas markets, costs associated with complying with new or amended laws and regulations and mitigating the increased cost of the new tariffs and duties affecting our business, declines in our stock price, reduced availability and less favorable terms of future borrowings, negative impacts on the valuation of our pension obligations, reduced credit-worthiness of our customers, and potential impairment of the carrying value of indefinite-lived intangible assets and goodwill.

25

Table of Contents

The Year Ended December 31, 2025 Compared to the Year Ended December 31, 2024

Operations

The following table provides highlights of our financial performance (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","","For the Years Ended December 31,"],["","","2025","","","2024","","","$ Change","","","% Change"],["Net sales:"],["Branded Products","","$","361,134","","","$","353,314","","","$","7,820","","","","2.2","%"],["Healthcare Apparel","","","115,866","","","","119,191","","","","(3,325",")","","","(2.8","%)"],["Contact Centers","","","92,520","","","","96,949","","","","(4,429",")","","","(4.6","%)"],["Net intersegment eliminations","","","(3,336",")","","","(3,778",")","","","442","","","","(11.7","%)"],["Consolidated net sales","","","566,184","","","","565,676","","","","508","","","","0.1","%"],["Gross margin:"],["Branded Products","","","123,712","","","","124,723","","","","(1,011",")","","","(0.8","%)"],["Healthcare Apparel","","","41,962","","","","45,746","","","","(3,784",")","","","(8.3","%)"],["Contact Centers","","","48,980","","","","52,207","","","","(3,227",")","","","(6.2","%)"],["Net intersegment eliminations","","","(1,790",")","","","(2,098",")","","","308","","","","(14.7","%)"],["Consolidated gross margin","","","212,864","","","","220,578","","","","(7,714",")","","","(3.5","%)"],["Selling and administrative expenses:"],["Branded Products","","","96,067","","","","94,384","","","","1,683","","","","1.8","%"],["Healthcare Apparel","","","39,550","","","","41,149","","","","(1,599",")","","","(3.9","%)"],["Contact Centers","","","42,385","","","","42,999","","","","(614",")","","","(1.4","%)"],["Intersegment Eliminations","","","(1,790",")","","","(2,098",")","","","308","","","","(14.7","%)"],["Other","","","23,263","","","","23,492","","","","(229",")","","","(1.0","%)"],["Consolidated selling and administrative expenses","","","199,475","","","","199,926","","","","(451",")","","","(0.2","%)"],["Interest expense","","","5,143","","","","6,358","","","","(1,215",")","","","(19.1","%)"],["Income before income tax expense","","","8,246","","","","14,294","","","","(6,048",")","","","(42.3","%)"],["Income tax expense","","","1,246","","","","2,290","","","","(1,044",")","","","(45.6","%)"],["Net income","","","7,000","","","","12,004","","","","(5,004",")","","","(41.7","%)"],["EBITDA(1)","","$","25,744","","","$","34,097","","","$","(8,353",")","","","(24.5","%)"]]
[[/GREPCENT_TABLE]]

(1) Please refer to "Non-GAAP Financial Measure" below for a reconciliation of EBITDA to net income.

26

Table of Contents

Net Income

The Company generated net income of $7.0 million during the year ended December 31, 2025 and net income of $12.0 million during the year ended December 31, 2024. The decrease in net income during the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to decreases in gross margins in all three of our reportable segments, partially offset by a decrease in interest expense.

EBITDA

EBITDA was $25.7 million and $34.1 million during the years ended December 31, 2025 and 2024, respectively. EBITDA for the year ended December 31, 2025 compared to the year ended December 31, 2024 decreased primarily due to lower gross margins in all three of our reportable segments. For a reconciliation of EBITDA to net income, its most directly comparable financial measure calculated and presented in accordance with GAAP, please read “Non-GAAP Financial Measure” below.

Net Sales

Net sales for the Company increased 0.1% or $0.5 million, for the year ended December 31, 2025 compared to the year ended December 31, 2024. The increase was primarily attributable to a net sales increase in our Branded Products reportable segment.

Branded Products net sales increased 2.2%, or $7.8 million, for the year ended December 31, 2025 compared to the year ended December 31, 2024. The increase was primarily due to

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/SGC/mda/fy2025/
All MD&A years: /company/SGC/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/SGC/mda/fy2024/): filed 2025-03-11; accession 0001437749-25-007055 (https://www.sec.gov/Archives/edgar/data/95574/000143774925007055/sgc20241231_10k.htm)
- [FY 2023 MD&A](/company/SGC/mda/fy2023/): filed 2024-03-14; accession 0001437749-24-007685 (https://www.sec.gov/Archives/edgar/data/95574/000143774924007685/sgc20231231_10k.htm)
- [FY 2022 MD&A](/company/SGC/mda/fy2022/): filed 2023-03-20; accession 0001437749-23-007261 (https://www.sec.gov/Archives/edgar/data/95574/000143774923007261/sgc20221231_10k.htm)
- [FY 2021 MD&A](/company/SGC/mda/fy2021/): filed 2022-03-23; accession 0001437749-22-006982 (https://www.sec.gov/Archives/edgar/data/95574/000143774922006982/sgc20211231_10k.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2300 Apparel & Other Finishd Prods of  Fabrics & Similar Matl) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/SGC.md · JSON record: /company/SGC.json · verified financials: /company/SGC/financials.json / /company/SGC/financials.csv · machine TOC for the whole site: /llms.txt